> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 12 Observations in Baxter Oncology FDA-483
- URL: https://www.fdaweb.com/12-observations-in-baxter-oncology-fda-483/
- Published: 2026-02-03T12:00:00.000Z
- Updated: 2026-09-14T15:32:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160595

FDA has released the form FDA-483 with 12 observations from a 9/18-9/26/2025 inspection at the Baxter Oncology drug manufacturing facility in Halle, North Rhine-Westphalia, Germany. The specific observations were:

- failure of procedures designed to prevent microbiological contamination of drug products purporting to be sterile, to include adequate validation of the aseptic and sterilization process;
- failure to establish and follow procedures designed to prevent microbiological contamination of drug products purporting to be sterile;
- aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions;
- equipment used in the manufacture, processing, packing, or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance;
- failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has been already distributed;
- aseptic processing areas are deficient regarding the system for monitoring environmental conditions;
- failure of laboratory controls to include the establishment of scientifically sound and appropriate sampling plans designed to assure that in-process materials conform to appropriate standards of identity, strength, quality, and purity;
- failure to clean and maintain equipment and utensils at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality, or purity of the drug product;
- failure to establish adequate written procedures for production and process controls designed to assure that drug products have the identity, strength, purity, and quality that they are purported or represented to possess;
- failure to follow procedures for the preparation of master production and control records;
- the quality control unit lacks authority to review production records to ensure that no errors have occurred; and
- buildings used in the manufacture, processing, packing, or holding of drug products are not free of infestation by rodents, birds, insects, and other vermin.